( Preclinical Studies Show 227Th-rituxim...)Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood,Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood
Preclinical Studies Show 227Th-rituximab More Effective at Killing CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab (Zevalin)
OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announces that a research paper showing the potential of its TH-1 technology for targeted cancer therapy has been published by the leading medical journal, Blood, the official journal of the American Society of Hematology (ASH).
Algeta's TH-1 technology links Thorium-227, which emits alpha particles, to cancer-targeting molecules such as antibodies. Alpha-emitting radionuclides are of considerable interest in the treatment of cancer as they are highly destructive to tumour cells but have very short range. Linking this radionuclide to tumour-seeking molecules creates a conjugate with the potential to specifically seek and destroy cancers while leaving surrounding healthy tissues undamaged.
The Blood paper describes how researchers from the Norwegian Radium Hospital (Oslo) in collaboration with Professor Oliver Press at the Fred Hutchison Cancer Research Center (Seattle, USA) and Algeta have linked Thorium-227 to the monoclonal antibody rituximab to create 227Th-rituximab and demonstrated its potent anti-tumour effects.
Rituximab binds to a specific molecule on the cancer cell surface called CD20 and is marketed in USA as Rituxan® by Genentech and Biogen-Idec for the treatment of certain types of non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis, and as MabThera® by Roche for the treatment of certain types of NHL. Rituximab-based therapies generated global sales of nearly $6 billion in 2006.
In in vitro studies 227Th-rituximab killed CD20-positive lymphoma cells at low doses (Bq/ml) while in preclinical models, a single injection of 227Th-rituximab induced complete tumor regression in up to 60% of tumours without apparent toxicity.
<'"/>
Related medicine technology :
1. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
9. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
10. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
11. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
Post Your Comments:
(Date:11/20/2009)... , NEW YORK, Nov. 20 ,, Re...h report is available in its catalogue. ,, Glo... http://www.reportlinker.com/p0164741/Global-Mark...=prnewswire&utm_medium=pr&utm_campaign=prn...sy devices includes the spring loaded core needle ...
(Date:11/20/2009)..., NATICK, Mass. and LONDON, Nov. 20 /PRNewswire...: BSX ) today announced that it has received 510...ration (FDA) and CE Mark approval to market its Wa...e treatment of malignant esophageal strictures (ob...ctable or non-resectable esophageal cancer. ,,...
(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-U...mes article that questions why currently availabl...ancers are being ignored, ECRI Institute, an indep...ap to the evidence on Finasteride for Prevention ... November 13, 2009, New York Times article, " Dr...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Heartburn Drugs May Contribute to the Problem 50969 1Heartburn Drugs May Contribute to the Problem 50969 2Heartburn Drugs May Contribute to the Problem 50969 3Pharmacyclics Sets Record Date for Rights Offering 50966 1Pharmacyclics Sets Record Date for Rights Offering 50966 2Pharmacyclics Sets Record Date for Rights Offering 50966 3CareFusion Corporation Launches International Jazz Festival Series 50963 1CareFusion Corporation Launches International Jazz Festival Series 50963 2CareFusion Corporation Launches International Jazz Festival Series 50963 3CareFusion Corporation Launches International Jazz Festival Series 50963 4CareFusion Corporation Launches International Jazz Festival Series 50963 5[0] Reportlinker Adds Global Markets for Breast Biopsy Devices 2009[0] Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent[0] ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists
... (OTCBB: ORMP) ( http://www.oramed.com ), a develo... it will hold a conference call on August 6,2008 a... 2A clinical trials,of its flagship product, ORMD ... trial is focused on assessing the safety and effi... the successfully completed,Phase 1 studies in Isr...
...(OTC Bulletin Board: ANPG), reported today that it...I) announced that its EnviroTru(R),disinfectant ha...tment of,Management Services (DMS) in the State of...r, A World of Green, LLC(TM) ( http://www.aworldo...u(R) assigned under the code which now,permits Sta...
Other Medicine Technology:Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 3(Date:11/20/2009)...ON, NJ, Nov. 20 /PRNewswire-FirstCall/ - NUCRYST P...l Meeting of Shareholders will be held on Monday, ...o consider approval of two special resolutions. Th...rize the sale of all or substantially all of the a...ded for in the asset purchase agreement dated Nove...
(Date:11/20/2009)...HINGTON, Nov. 20 The Un...he Senate to make essential changes its health ref...abortion funding and conscience protection on abor... and include strong provisions for adequate afford...h care bill an "enormous disappointment" that crea...
(Date:11/20/2009)... Senators and Congressmen in Competitive Re-...alth Care Vote , Washingt...ongressmen running for re-election next year in ra...rlie Cook, may come to regret voting for House Spe...ing to a breaking Zogby International/ O’Lea...
(Date:11/20/2009)... Nov. 20 The American D...and Drug Administration (FDA) to establish appropr.... ,, Citing concern about the safety of whiten...he benefit of professional consultation or examina...pplication of chemically based tooth whitening or ...
(Date:11/20/2009)...AIFA, Israel, November 20 /PRNewswire-FirstCall/ -... http://www.CVSLMEDICAL.COM , a leading,developer ...ay announced that,the company,s Board of Directors...rope, Canada and the Far East for its proprietary ...or all angioplasty (PCTA) procedures. , C...
Breaking Medicine News(10 mins):Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2[0] NUCRYST Announces Special Meeting of Shareholders[0] U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability[0] Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill [0] American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products[0] Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East
... new weapon is being investigated.//
Scientist...edient -oligo fructose, on obese human subjects. ...the natural fiber seen in baby foods, cereals and ...ke peptide that was responsible for a feeling of s...
...munication between clinicians in the Intensive Car... significantly reduces feelings of stress,// anxie...g to a study that appears in the February 1, 2007 ...National Institutes of Health (NIH), showed that t...
...vels during women’s menstrual cycles affect the re... imaging study at the National Institute of// Ment...itutes of Health (NIH), has revealed.
While w...o a phase when estrogen and progesterone are prese...
...to grant product patent for Glivec, the cancer dru...esult Novartis may not be able to conduct// their ...re the countries where Novartis conducts its resea... government could hamper the launch of their paten...
...re has been a marked increase in allergic reaction...ed eight times during a 30 year period.// Teenager...sporting different hair colors, in keeping with a ...esearchers are pressing for a wider debate about t...
...of Michigan Medical Center have, for the first tim.../ Their work indicates that these cells are likely...ression, and metastasis that define this deadly ca...atic cancer in half of mice tested. They also foun...
Other Medicine News:Health News:Communication in the ICU to Be Strengthened 2Health News:Communication in the ICU to Be Strengthened 3Health News:NIMH Studies Woman’s Hormonal Cycl 2Health News:Scientists Identify Pancreatic Cancer Stem Cells 2Health News:Scientists Identify Pancreatic Cancer Stem Cells 3| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |